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Abstract
The article explores different deep convolutional neural network architectures trained and
tested on posteroanterior chest X-rays of 327 patients who are healthy (152 patients), di-
agnosed with COVID-191 (125), and other types of pneumonia (48), of which Severe Acute
Respiratory Syndrome (16), Streptococcus (13), Klebsiella (1), Legionellosis (2), Pneu-
mocystis Jiroveci Pneumonia (13), Acute Respiratory Distress Syndrome not caused by
COVID-19 (4), and Chlamydia Pneumoniae (1). In particular, this paper looks at the
deep convolutional neural networks VGG16 and VGG19 (Simonyan and Zisserman, 2015),
InceptionResNetV2 and InceptionV3 (Szegedy et al., 2016), as well as Xception (Chollet,
2017), all followed by a flat multi-layer perceptron and a final 30% drop-out.
The paper has found that the best performing network is VGG16 with a final 30% drop-out
trained over 3 classes (COVID-19, No Finding, Other Pneumonia). It has a cross-validated
training accuracy of 93.9(±3.4)%, a COVID-19 sensitivity of 87.7(−1.9,+2)%, and a No
Finding sensitivity of 96.8(±0.8)%. The respective cross-validated values on the testing
set are 84.1(±13.5)%, 87.7(−1.9, 2)%, and 96.8(±0.8)%.2 The model optimizer was Adam
(Kingma and Lei-Ba, 2015) with a 0.0001 learning rate, and categorical cross-entropy loss.
It is hoped that, once this research will be put to practice in hospitals, healthcare profes-
sionals will be able in the medium to long-term to diagnosing through machine learning
tools possible pneumonia, and if detected, whether it is linked to a COVID-19 infection,
allowing the detection of new possible COVID-19 foyers after the end of possible ”stop-
and-go” lockdowns as expected by Ferguson et al. (2020) until a vaccine is found and
widespread. Furthermore, in the short-term, it is hoped practitioners can compare the di-
agnosis from the deep convolutional neural networks with possible RT-PCR testing results,
and if clashing, a Computed Tomography could be performed as they are more accurate in
showing COVID-19 pneumonia (Ai et al., 2020; Wang et al., 2020; Xu et al., 2020).
1. Referring to the coronavirus originating from Wuhan, mainland China, and discovered in 2019.
2. The values in brackets are the differences between the estimated values for the measures listed and the
left or right boundary of the 95% confidence interval after Stratified 5-Fold cross-validation. The inverse
cumulative distribution function value is taken from a t-distribution with 4 degrees of freedom.
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Abbreviations
Listed by alphabetical order
• 2D-Conv(m,M): 2-dimensional convolution layer of M channels of m×m kernel
• AI: Artificial Intelligence
• ARDS: Acute Respiratory Distress Syndrome
• COVID-19: Novel Coronavirus 2019 SARS-n-CoV-2
• CT: Computed Tomography
• DropOut(p): drop-out between two perceptron layers with probability p
• Layer(n): flat perceptron layer made of n neurons
• MERS: Middle East Respiratory Syndrome
• MaxPool(d, s): MaxPool layer of d× d pool and s× s stride
• Output(f): output from the neural network through some activation function f
• PA (X-ray): Posteroanterior X-ray
• RT-PCR (test): Reverse Transcription Polymerase Chain Reaction test
• SARS: Severe Acute Respiratory Syndrome
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1. Introduction, Aims, & State-of-the-Art
As the writing of this article, there is a significant outbreak of COVID-19, which can lead to
pneumonia, visible to medical imaging methods such as X-rays or CT scans. This pneumo-
nia has also been detected in RT-PCR COVID-19 positive patients who did not have any
known underlying health conditions (Cheng et al., 2020). Epidemiology research has tried
to find the effective reproduction number before and after lockdowns and school closures, as
well as estimating the real number of people infected by COVID-19 through mathematical
models (Ferguson et al., 2020; Flaxman et al., 2020) or seroprevalence studies (Bendavid
et al., 2020). In particular, Flaxman et al. (2020) estimated that up to March 28, 2020, be-
tween 1.2% and 5.4% of the population had been COVID-19 infected in the United Kingdom
(i.e., between roughly 800,000 and 3,600,000 residents of the United Kingdom). Antibody
seroprevalence studies showed that between 2.24% and 3.37% of the Santa Clara, CA pop-
ulation contracted COVID-19 up to April 4, 2020 (Bendavid et al., 2020), and around 21%
of the New York City, NY population contracted the disease according to the Governor of
New York. So far, the most advanced clinical trials for a potential vaccine are located in
the United States, the United Kingdom, and Germany, and such a vaccine could only be
available in fall 2020 at the earliest for healthcare professionals.
Wang et al. (2020) have applied deep convolutional neural networks on 1,065 CT images
from the lungs of pathogen-confirmed COVID-19 cases (325 patients) along with those pre-
viously diagnosed with typical viral pneumonia (740 patients) not provoked by coronavirus.
The internal validation in that research achieved a total accuracy of 89.5% with specificity
of 88% and sensitivity of 87%, while the external testing data-set showed a total accuracy of
79.3% with specificity of 83% and sensitivity of 67%. 54 patients part of the study had the
first two nucleic acid test results for COVID-19 were negative, of which 46 were predicted
as COVID-19 positive by the algorithm with the probability of 85.2%, which could further
prove the very low accuracy of such tests. Indeed, Ai et al. (2020) discovered that of the
patients with negative RT-PCR results, 75% had positive chest CT findings of which 48%
were considered as highly likely cases of COVID-19.
Similarly, Xu et al. (2020) found that the real time reverse RT-PCR detection of viral
RNA from sputum or nasopharyngeal swab has a relatively low positive rate to determine
COVID-19 positiveness. After training ResNet-like neural networks on CT images of pa-
tients showing COVID-19 (357 images), Other Viral Pneumonia (390), and No Finding
(963), that research found respective sensitivities of 81.5%, 75.4%, and 97.8%, with an
overall accuracy on the benchmark data-set of 86.7%. These are seemingly similar results
to Wang et al. (2020).
An attempt of training deep neural networks on PA chest X-rays, where some of which
showed a COVID-19 pathology, was made by Narin et al. (2020) with other parts of the
same data-set used in this research, although they only used the classes COVID-19 (50
images) and No Finding (50), meaning their neural networks could, in principle, categorize
non-COVID-19 pneumoniae as such if presented by such X-ray. This explains the high ac-
curacies and other measures that they have found for the InceptionResNetV2, InceptionV3,
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and ResNet50 architectures. Indeed, they reached an accuracy of 98%, a COVID-19 sen-
sitivity of 96%, and a specificity value of 100% for ResNet50 on the external testing data.
These are the cross-validated values through standard 5-Fold. Furthermore, the data-set
was relatively small.
There are two main goals to this research: (1) in the medium to long-term, being able to
diagnose through machine learning tools possible pneumonia, and if detected, whether it
is linked to a coronavirus infection or other, allowing the detection of new possible coro-
navirus foyers after the end of possible ”stop-and-go” lockdowns as expected by Ferguson
et al. (2020) until a vaccine is found and widespread. (2) Furthermore, in the short-term,
it can allow practitioners to compare the diagnosis from the deep convolutional neural net-
works in this paper with possible RT-PCR testing results – if clashing, a chest CT could
be done as they are more accurate in showing COVID-19 pneumonia as shown by Ai et al.
(2020); Wang et al. (2020); Xu et al. (2020).
This research focuses on PA chest X-rays because, although they can be less accurate to
diagnose COVID-19 than CT imaging, they are more common in hospitals and relatively
cheaper to perform. Hence, training neural networks on PA chest X-rays could lead to
greater generalization and application in hospitals around the world, and CT imaging would
only be used for cases where patients are pathogen-confirmed COVID-19 through RT-PCR
testing but the AI diagnoses No Finding, or when the AI diagnoses the patients as highly-
likely COVID-19 but the RT-PCR tests are negative.
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2. The Data
The data has been collected from Cohen et al. (2020) and Kermany et al. (2018). The first
source (Cohen et al., 2020) had predominantly data from ill patients, and therefore the
paper partially uses the second data-set (Kermany et al., 2018) which is made of healthy
patients only (only partially otherwise there would be an over-representation).
All training X-rays have been resized to a shape 182×182. After train-test split, all train-
ing X-rays are allowed to rotate up to 50 degrees, are feature-wise standardized using
statistics from the entire set, can have their widths and heights shifted by up to 20%, are
allowed a shear intensity of up to .25 degrees in the counter-clockwise direction, as well as
a zooming/de-zooming range of ±10%, a channel shifting range of .2, and can flip either
horizontally or vertically. Missed pixels are filled through constant filling. This allows to
also expand the number of training images. These allowed transformations for the training
set are detailed in the Table 1.
(a) Lungs of a healthy
patient.
(b) Lungs of a COVID-
19 infected patient.
(c) Lungs of a chlamy-
dia infected patient.
(d) Lungs of a patient
suffering ARDS.
(e) Final distribution of diagnoses by the healthcare professionals based on the PA chest X-rays
in the combined data-sets.
Figure 1: Examples of PA chest X-rays in the data-set in Figures 1a to 1d, and distribution
of the diagnoses based on the PA chest X-rays in Figure 1e.
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Feature Comment
Resizing to 182× 182 in RGB, resulting in (182, 182, 3) arrays
Rotation up to ±50 degrees
Standardization feature-wise through training set statistics
Width shift up to ±20%
Height shift up to ±20%
Shear intensity up to .25 degrees counter-clockwise
Zooming & de-zooming up to ±10%
Channel shifting in the range of 20%
Horizontal & vertical flip True
Table 1: Possible transformations of the images in the training set before being introduced
to the convolutional neural networks.
Figure 1e shows the final distribution of illness diagnoses following the reading of the PA
chest X-rays by the healthcare professionals.
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3. VGG16
The architecture of the first considered deep convolutional neural network follows the
VGG16 architecture proposed by Simonyan and Zisserman (2015), and is detailed in Table
2. Once trained over 200 epochs on a data-set of over 14 million 224×224 images belonging
to 1,000 classes based on the Large Scale Visual Recognition Challenge 2014 (ILSVRC2014),
this deep convolutional neural network achieved 92.7% top-5 test accuracy. In this research,
we kept the weights for pre-training following the ILSVRC2014. The optimizer is Adam
(Kingma and Lei-Ba, 2015) with categorical cross-entropy loss, learning rate 0.0001, and
ran over 200 epochs.
Step type Computations Name
First 2D-Convolutions
2D-Conv(3, 64) 2D-Conv 111
2D-Conv(3, 64) 2D-Conv 112
First 2D-Maximum pooling MaxPool(2, 2) Pool 11
Second 2D-Convolutions
2D-Conv(3, 128) 2D-Conv 121
2D-Conv(3, 128) 2D-Conv 122
Second 2D-Maximum pooling MaxPool(2, 2) Pool 12
Third 2D-Convolutions
2D-Conv(3, 256) 2D-Conv 131
2D-Conv(3, 256) 2D-Conv 132
2D-Conv(3, 256) 2D-Conv 133
Third 2D-Maximum pooling MaxPool(2, 2) Pool 13
Fourth 2D-Convolutions
2D-Conv(3, 512) 2D-Conv 141
2D-Conv(3, 512) 2D-Conv 142
2D-Conv(3, 512) 2D-Conv 143
Fourth 2D-Maximum pooling MaxPool(2, 2) Pool 14
Fifth 2D-Convolutions
2D-Conv(3, 512) 2D-Conv 151
2D-Conv(3, 512) 2D-Conv 152
2D-Conv(3, 512) 2D-Conv 153
Fifth 2D-Maximum pooling MaxPool(2, 2) Pool 15
Flat portion
Flatten Flat 11
Layer(4096) Layer 11
Layer(4096) Layer 12
Layer(1000) Layer 13
Batch Normalization Norm 11
Layer(256) Layer 14
DropOut(p) Drop 11
Output Output(softmax) Out 1
Table 2: VGG16 configuration (Simonyan and Zisserman, 2015) with an added flat portion
that has some drop-out rate p. The activation function is Rectified Linear Unit (ReLU)
throughout. The total number of parameters for this architecture is 17,994,563 for 182×182
images.
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We perform the Stratified 5-Fold cross-validation of the VGG16 with 30% final drop-out,
and the results are as shown in Table 3.
Internal / Training Set
Measure LHS 95% CI Value RHS 95% CI
Loss -0.135 0.105 0.339
Accuracy 0.905 0.939 0.973
Flat AUC 0.971 0.974 0.976
COVID-19 Recall 0.858 0.877 0.897
No Finding Recall 0.960 0.968 0.976
Other Pneumonia Recall 0.500 0.534 0.568
External / Testing Set
Measure LHS 95% CI Value RHS 95% CI
Loss -0.324 0.337 0.998
Accuracy 0.706 0.841 0.976
Flat AUC 0.970 0.974 0.977
COVID-19 Recall 0.858 0.877 0.897
No Finding Recall 0.960 0.968 0.976
Other Pneumonia Recall 0.500 0.534 0.568
Table 3: Cross-validated performance measures (rounded to the thousandth) of the VGG16
neural network outlined in Table 2 through Stratified 5-Fold and 200 epochs, learning rate
of 0.0001. The 95% confidence interval were computed through the t-distribution with 4
degrees of freedom.
In this case, we find satisfactory accuracies for the training and testing set, of respectively
94% and 84%, although the 95% confidence is quite large for the latter. Interestingly, the
COVID-19 sensitivity remains high with short-range confidence intervals. A 88% COVID-
19 sensitivity is similar to Wang et al. (2020) for the training set, but significantly higher
for the testing set. In clinical terms, around 88% of those diagnosed or tested COVID-19
positive are identified as such by the neural network outlined in Table 2. Similarly, we found
that the No Finding sensitivity, i.e., the percentage of lung-healthy patients identified as
such, is of 97% for both the training and testing set.
On the other hand, the sensitivity for pneumonia diseases other than COVID-19 is poor
(at 53% for both the training and testing sets), meaning the neural network has difficul-
ties differentiating COVID-19 and other pneumoniae. For such differentiation, Wang et al.
(2020) found a sensitivity of 67%, which is better, although they only used two classes,
namely COVID-19 and Other Pneumonia. It is possible that this improved sensitivity is
due to the fact that Wang et al. (2020) trained their neural networks on CT images, and
not on PA X-rays, which tend to better differentiate pathologies. Furthermore, there is an
under-representation of such label in our data-set, although we consider that it could be
representative of data-sets found in hospital during a COVID-19 epidemic.
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As we are dealing with a multi-class problem, the Flat AUC (Area Under the ROC Curve)
is not equivalent to the standard binary AUC. We here flattened the data into a single
label before AUC computation. In which case, each label-prediction pair is treated as
an individual data point. Therefore, this measure should not be very reliable, although
does procure some information on the ”overall” ROC of the neural network. It is found
to be of 97.4% for both the training and testing data-sets. Due to the construction of
this performance measure, it is better to compare it to other networks and may not carry
significance of the network alone – which is what we will do in the sections below.
4. InceptionResNetV2 & InceptionV3
The second architecture considered is a very deep convolutional neural network named In-
ceptionResNetV2 proposed by Szegedy et al. (2016), and it is described in the diagram
shown in Figure 2. Once trained over 200 epochs on the ImageNet data-set, this very deep
convolutional neural network achieved 95.3% top-5 test accuracy. In this research, we kept
the weights for pre-training after the above training, we use an Adam optimizer (Kingma
and Lei-Ba, 2015) with learning rate 0.0001, categorical cross-entropy loss, and 200 epochs.
In the architecture, max-pooling was performed for feature extraction.
Figure 2: Description diagram of the architecture of InceptionResNetV2, as detailed in
Szegedy et al. (2016). On the 182 × 182 data-set, this neural network has 54,737,123
parameters.
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The cross-validated performance measures, obtained through Stratified 5-Fold, for the In-
ceptionResNetV2 with final 30% drop-out are shown in Table 4.
Internal / Training Set
Measure LHS 95% CI Value RHS 95% CI
Loss 0.073 0.977 1.881
Accuracy 0.520 0.616 0.712
Flat AUC 0.906 0.918 0.931
COVID-19 Recall 0.673 0.708 0.744
No Finding Recall 0.911 0.918 0.925
Other Pneumonia Recall 0.351 0.433 0.514
External / Testing Set
Measure LHS 95% CI Value RHS 95% CI
Loss 0.488 1.411 2.335
Accuracy 0.457 0.612 0.765
Flat AUC 0.907 0.919 0.932
COVID-19 Recall 0.675 0.710 0.745
No Finding Recall 0.911 0.918 0.925
Other Pneumonia Recall 0.353 0.433 0.513
Table 4: Cross-validated performance measures (rounded to the thousandth) of the
InceptionResNetV2-like neural network outlined in Figure 2 through Stratified 5-Fold and
200 epochs, learning rate of 0.0001. The 95% confidence interval were computed through
the t-distribution with 4 degrees of freedom.
The performance results for InceptionResNetV2 tend here to be quite disappointing, mainly
because this architecture includes many batch normalizations (Ioffe and Szegedy, 2015).
During model training, the batches are normalized by their mean and variance, but in the
testing phase, the batches are normalized with respect to the changing average of observed
mean and variance, leading to lower accuracies for the type of data-set we are considering.
In particular, we found COVID-19 sensitivities for the InceptionResNetV2 network of
70.8(−3.5,+3.6)% and 71.0(±3.5)% for the internal and external validations respectively.
In medical terms, this is considered relatively poor, and seems indeed low even if we take
into account errors from RT-PCR testing or seroprevalence studies as showcased in Xu et al.
(2020). Furthermore, for the accuracies and COVID-19 sensitivities, the 95% confidence
interval implied by the Stratified 5-Fold cross-validation is wide, implying greater variance.
Hence, it is likely that training and testing on different but similar data-sets could lead to
very different performance results.
Similarly, we can compare the Flat AUC value with the VGG16-like network trained as
in the previous section. According to the measures gathered, the VGG16-like neural
network improved the internal and external Flat AUCs by approximately 6% compared
to the InceptionResNetV2-like neural network. Hence, we believe that the VGG16-like
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neural network is more appropriate for the data-set we are studying compared to the
InceptionResNetV2-like neural network.
In the case of the InceptionV3 convolutional neural network (Szegedy et al., 2015), with
the same optimizer, we find similar albeit slightly enhanced performance results compared
to InceptionResNetV2, as seen in Table 5.
Internal / Training Set
Measure LHS 95% CI Value RHS 95% CI
Loss -2.913 2.676 8.266
Accuracy 0.529 0.705 0.880
Flat AUC 0.908 0.931 0.954
COVID-19 Recall 0.689 0.779 0.870
No Finding Recall 0.928 0.941 0.953
Other Pneumonia Recall 0.421 0.491 0.561
External / Testing Set
Measure LHS 95% CI Value RHS 95% CI
Loss -0.757 3.477 7.711
Accuracy 0.477 0.691 0.905
Flat AUC 0.909 0.931 0.954
COVID-19 Recall 0.691 0.780 0.869
No Finding Recall 0.928 0.941 0.953
Other Pneumonia Recall 0.422 0.491 0.560
Table 5: Cross-validated performance measures (rounded to the thousandth) of the
InceptionV3-like neural network through Stratified 5-Fold and 200 epochs, learning rate
of 0.0001. The 95% confidence interval were computed through the t-distribution with 4
degrees of freedom.
5. VGG19
Due to the earlier success of VGG16, we consider the VGG19 deep convolutional neural
network architecture as showcased in Simonyan and Zisserman (2015), and again with 200
epochs, the Adam optimizer (Kingma and Lei-Ba, 2015), a learning rate of 0.0001, and
categorical cross-entropy loss. VGG19 is similar to VGG16, instead we add the following
convolutions (Simonyan and Zisserman, 2015):
• 2D-Conv(3, 256) after 2D Conv 133 in Table 2,
• 2D-Conv(3, 512) after 2D Conv 143 in Table 2,
• and 2D-Conv(3, 512) after 2D Conv 153 in Table 2.
The performance measures seen in Table 6 for the VGG19-like network are very similar than
those gathered for the VGG16-like network (Table 3) due to the very similar architecture. In
particular, we find that the added convolutions do not increase significantly the performance
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Internal / Training Set
Measure LHS 95% CI Value RHS 95% CI
Loss -0.056 0.082 0.220
Accuracy 0.902 0.927 0.953
Flat AUC 0.967 0.969 0.971
COVID-19 Recall 0.843 0.861 0.879
No Finding Recall 0.960 0.964 0.969
Other Pneumonia Recall 0.428 0.480 0.531
External / Testing Set
Measure LHS 95% CI Value RHS 95% CI
Loss -0.527 0.485 1.498
Accuracy 0.702 0.820 0.937
Flat AUC 0.967 0.969 0.970
COVID-19 Recall 0.843 0.861 0.879
No Finding Recall 0.960 0.964 0.968
Other Pneumonia Recall 0.427 0.479 0.531
Table 6: Cross-validated performance measures (rounded to the thousandth) of the VGG19-
like neural network through Stratified 5-Fold and 200 epochs, learning rate of 0.0001. The
95% confidence interval were computed through the t-distribution with 4 degrees of freedom.
measures, although we see that the 95% confidence intervals are shrunk. Furthermore, due
to these added convolutions, VGG19 is slightly more costly than VGG16 despite no big
improvement in the measures.
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6. Conclusion
A summary table of some of the performance measures for the neural networks all trained
over 200 epochs are shown in Table 7. Some of these measures are further shown in Figure 3.
As we can see from Table 7 and Figure 3, VGG16 performed best on all measures, al-
though VGG19 had a similar performance with lower variability. In particular, VGG16 had
Stratified 5-Fold cross-validated accuracies of 93.9(±3.4)% for the internal data-set and of
84.1(±13.5)% for the external data-set. Note that we have run all the training sessions with
200 epochs for comparability between the neural networks, and therefore this difference be-
tween the internal and external accuracies might be explained by over-fitting. Furthermore,
the COVID-19 sensitivity of the VGG16 neural network is of 87.7(−1.9, 2)% for both the
internal and external data-sets, suggesting efficiency of that network in correctly identifying
true COVID-19 positives. Idem for the No Finding sensitivity which is at 96.8(±0.8)%.
- Internal / Training Set External / Testing Set
Net Accuracy #1 Recall #2 Recall Accuracy #1 Recall #2 Recall
(1) 93.9+3.4−3.4% 87.7
+2.0
−1.9% 96.8
+0.8
−0.8% 84.1
+13.5
−13.5% 87.7
+2.0
−1.9% 96.8
+0.8
−0.8%
(2) 92.7+2.6−2.5% 86.1
+1.8
−1.8% 96.4
+0.5
−0.4% 82.0
+11.7
−11.8% 86.1
+1.8
−1.8% 96.4
+0.4
−0.4%
(3) 61.6+9.6−9.6% 70.8
+3.6
−3.5% 91.8
+0.7
−0.7% 61.2
+15.3
−15.5% 71.0
+3.5
−3.5% 91.8
+0.7
−0.7%
(4) 70.5+17.5−17.6% 77.9
+9.1
−9.0% 94.1
+1.2
−1.3% 69.1
+21.4
−21.4% 78.0
+8.9
−8.9% 94.1
+1.2
−1.3%
(5) 65.3+21.8−21.8% 75.0
+8.9
−8.8% 89.5
+2.9
−2.9% 61.4
+19.6
−19.5% 75.1
+8.8
−8.8% 89.5
+2.9
−2.8%
Table 7: Cross-validated (Stratified 5-Fold) internal and external measures for each of
the models considered, rounded to the closest thousandth. Here, #1 Recall refers to the
sensitivity of the neural network on the COVID-19 categorical variable, and #2 Recall the
sensitivity on the No Finding categorical variable. Networks: (1) VGG16 (Simonyan and
Zisserman, 2015), (2) VGG19 (Simonyan and Zisserman, 2015), (3) InceptionResNetV2
(Szegedy et al., 2016), (4) InceptionV3 (Szegedy et al., 2016), and (5) Xception (Chollet,
2017), all with a 30% final drop-out.
One topic of research that could be pursued following this paper is the creation of a spe-
cific deep neural network tailored for the data-set made of PA chest X-rays. This research
would be dependent on the easy access of a greater database of PA chest X-rays COVID-
19 positive patients (through CT diagnosis, RT-PCR or seroprevalence testing), as well as
the computational capabilities of large-scale training of very deep convolutional networks.
Furthermore, such tailored network could make it harder to share it to hospitals, and as a
consequence making it less prone to front-line applications.
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Figure 3: Performance measures of various neural networks on the data-set of PA chest
X-rays.
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7. Limits of this paper
The biggest limit to this research is by far the data-set. The data-set collected was small
after balancing for the number of COVID-19 positive cases, and still was quite unbalanced
as the class ”Other Pneumonia” was under-represented. Furthermore, the data includes PA
chest X-rays from a multitude of hospitals, which could have lowered the accuracies and
sensitivities.
It is also clear that the predictions on a PA chest X-ray given by the trained deep neural
networks cannot be relied upon alone. Its best use is in conjunction of clinical tests (such
as pathogen-RT-PCR or seroprevalence testing), or professional diagnosis based on other
clearer medical imaging methods such as CT scans.
8. For hospitals
Certified hospitals can request the code by contacting the author and / or Imperial College
London at pierre.moutounet-cartan17@imperial.ac.uk, as well as for explanation of how to
use it with their own data-set (or a collective data-set between ”sister” hospitals).
There are two main goals to this research to help hospitals:
• in the medium to long-term, being able to diagnose through machine learning tools
possible pneumonia, and if detected, whether it is linked to a coronavirus infection
or other, allowing the detection of new possible coronavirus foyers after the end of
possible ”stop-and-go” lockdowns as expected by Ferguson et al. (2020) until a vaccine
is found and widespread;
• in the short-term, it can allow practitioners to compare the diagnosis from the deep
convolutional neural networks in this paper with possible RT-PCR testing results – if
clashing, a chest CT could be done as they are more accurate in showing COVID-19
pneumonia as shown by Ai et al. (2020); Wang et al. (2020); Xu et al. (2020).
This research focuses on PA chest X-rays because, although they can be less accurate to
diagnose COVID-19 than CT imaging, they are more common in hospitals and relatively
cheaper to perform. Hence, training neural networks on PA chest X-rays could lead to
greater generalization and application in hospitals around the world, and CT imaging would
only be used for cases where patients are pathogen-confirmed COVID-19 through RT-PCR
testing but the AI diagnoses No Finding, or when the AI diagnoses the patients as highly-
likely COVID-19 but the RT-PCR tests are negative.
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